Targeting IL-10 in Auto-immune Diseases

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 37-49

  Tian, Guo ^a   Li, Jiao Long ^a   Wang, De Guang ^a   Zhou, Dian ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Auto immune diseases; IL 10; Therapeutic target

Indexed keywords

INTERLEUKIN 10;

ANIMAL; AUTOIMMUNE DISEASES; DEFICIENCY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-10; MOLECULAR TARGETED THERAPY;

EID: 84906281803     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9903-x     Document Type: Review

References (136)

1. Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annual Review of Immunology, 29, 71-109.
2. Crozat, K., Vivier, E., & Dalod, M. (2009). Crosstalk between components of the innate immune system: Promoting anti-microbial defenses and avoiding immunopathologies. Immunological Reviews, 227(1), 129-149.
3. Ding, Y., Qin, L., Zamarin, D., Kotenko, S. V., Pestka, S., Moore, K. W., et al. (2001). Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. Journal of immunology, 167(12), 6884-6892.
4. Cui, H. D., Qi, Z. M., Yang, L. L., Qi, L., Zhang, N., Zhang, X. L., et al. (2011). Interleukin-10 receptor expression and signalling were down-regulated in CD4(+) T cells of lupus nephritis patients. Clinical and Experimental Immunology, 165(2), 163-171.
5. Wang, B., Zhu, J. M., Fan, Y. G., Xu, W. D., Cen, H., Pan, H. F., et al. (2013). Association of the -1082G/A polymorphism in the interleukin-10 gene with systemic lupus erythematosus: A meta-analysis. Gene, 519(2), 209-216.
6. Park, Y. B., Lee, S. K., Kim, D. S., Lee, J., Lee, C. H., & Song, C. H. (1998). Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 16(3), 283-288.
7. Henningsson, L., Eneljung, T., Jirholt, P., Tengvall, S., Lidberg, U., van den Berg, W. B., et al. (2012). Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS ONE, 7(11), e49731.
8. Ying, B., Shi, Y., Pan, X., Song, X., Huang, Z., Niu, Q., et al. (2011). Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis. Molecular Biology Reports, 38(1), 379-385.
9. Huizinga, T. W., Keijsers, V., Yanni, G., Hall, M., Ramage, W., Lanchbury, J., et al. (2000). Are differences in interleukin 10 production associated with joint damage? Rheumatology, 39(11), 1180-1188.
10. Origuchi, T., Kawasaki, E., Ide, A., Kamachi, M., Tanaka, F., Ida, H., et al. (2003). Correlation between interleukin 10 gene promoter region polymorphisms and clinical manifestations in Japanese patients with Sjogren's syndrome. Annals of the Rheumatic Diseases, 62(11), 1117-1118.
11. Bertorello, R., Cordone, M. P., Contini, P., Rossi, P., Indiveri, F., Puppo, F., et al. (2004). Increased levels of interleukin-10 in saliva of Sjogren's syndrome patients. Correlation with disease activity. Clinical and Experimental Medicine, 4(3), 148-151.
12. Hesse, D., Krakauer, M., Lund, H., Sondergaard, H. B., Limborg, S. J., Sorensen, P. S., et al. (2011). Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? European Journal of Neurology, 18(2), 266-272.
13. Correa, F., Hernangomez-Herrero, M., Mestre, L., Loria, F., Docagne, F., & Guaza, C. (2011). The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain, Behavior, and Immunity, 25(4), 736-749.
14. Wilke, C. M., Wang, L., Wei, S., Kryczek, I., Huang, E., Kao, J., et al. (2011). Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. Journal of Translational Medicine, 9, 217.
15. Franke, A., McGovern, D. P., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., et al. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42(12), 1118-1125.
16. Noguchi, E., Homma, Y., Kang, X., Netea, M. G., & Ma, X. (2009). A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nature Immunology, 10(5), 471-479.
17. Darabi, K., Jaiswal, R., Hostetler, S. G., Bechtel, M. A., Zirwas, M. J., & Witman, P. (2009). A new kid on the block: IL-10+ regulatory B cells and a possible role in psoriasis. The Journal of Pediatric Pharmacology and Therapeutics: JPPT, 14(3), 148-153.
18. Glowacka, E., Lewkowicz, P., Rotsztejn, H., & Zalewska, A. (2010). IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils-fibroblasts interaction in psoriasis. Advances in Medical Sciences, 55(2), 254-260.
19. Asadullah, K., Sterry, W., Stephanek, K., Jasulaitis, D., Leupold, M., Audring, H., et al. (1998). IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. The Journal of Clinical Investigation, 101(4), 783-794.
20. Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989). Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. The Journal of Experimental Medicine, 170(6), 2081-2095.
21. Fillatreau, S., Gray, D., & Anderton, S. M. (2008). Not always the bad guys: B cells as regulators of autoimmune pathology. Nature Reviews Immunology, 8(5), 391-397.
22. Mauri, C., Gray, D., Mushtaq, N., & Londei, M. (2003). Prevention of arthritis by interleukin 10-producing B cells. The Journal of Experimental Medicine, 197(4), 489-501.
23. Maynard, C. L., & Weaver, C. T. (2008). Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunological Reviews, 226, 219-233.
24. Saraiva, M., Christensen, J. R., Veldhoen, M., Murphy, T. L., Murphy, K. M., & O'Garra, A. (2009). Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity, 31(2), 209-219.
25. O'Garra, A., & Vieira, P. (2007). T(H)1 cells control themselves by producing interleukin-10. Nature Reviews Immunology, 7(6), 425-428.
26. Anderson, C. F., Oukka, M., Kuchroo, V. J., & Sacks, D. (2007). CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. The Journal of Experimental Medicine, 204(2), 285-297.
27. Shoemaker, J., Saraiva, M., & O'Garra, A. (2006). GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. Journal of Immunology, 176(6), 3470-3479.
28. Chang, H. D., Helbig, C., Tykocinski, L., Kreher, S., Koeck, J., Niesner, U., et al. (2007). Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. European Journal of Immunology, 37(3), 807-817.
29. Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., et al. (2008). Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nature Immunology, 9(12), 1341-1346.
30. Boden, E. K., & Snapper, S. B. (2008). Regulatory T cells in inflammatory bowel disease. Current Opinion in Gastroenterology, 24(6), 733-741.
31. Li, H., Edin, M. L., Bradbury, J. A., Graves, J. P., DeGraff, L. M., Gruzdev, A., et al. (2013). Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB. American Journal of Respiratory and Critical Care Medicine, 187(8), 812-822.
32. Wolk, K., Witte, E., Witte, K., Warszawska, K., & Sabat, R. (2010). Biology of interleukin-22. Seminars in Immunopathology, 32(1), 17-31.
33. Dillon, S., Agrawal, S., Banerjee, K., Letterio, J., Denning, T. L., Oswald-Richter, K., et al. (2006). Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. The Journal of Clinical Investigation, 116(4), 916-928.
34. Boonstra, A., Rajsbaum, R., Holman, M., Marques, R., Asselin-Paturel, C., Pereira, J. P., et al. (2006). Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. Journal of Immunology, 177(11), 7551-7558.
35. Ryan, J. J., Kashyap, M., Bailey, D., Kennedy, S., Speiran, K., Brenzovich, J., et al. (2007). Mast cell homeostasis: A fundamental aspect of allergic disease. Critical Reviews in Immunology, 27(1), 15-32.
36. Grimbaldeston, M. A., Nakae, S., Kalesnikoff, J., Tsai, M., & Galli, S. J. (2007). Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nature Immunology, 8(10), 1095-1104.
37. Jenkins, J. K., Malyak, M., & Arend, W. P. (1994). The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine and Cytokine Research, 13(1), 47-54.
38. de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991). Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. The Journal of Experimental Medicine, 174(5), 1209-1220.
39. Takanaski, S., Nonaka, R., Xing, Z., O'Byrne, P., Dolovich, J., & Jordana, M. (1994). Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. The Journal of Experimental Medicine, 180(2), 711-715.
40. Nakajima, H., Gleich, G. J., & Kita, H. (1996). Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils. Journal of Immunology, 156(12), 4859-4866.
41. Bogdan, C., Vodovotz, Y., & Nathan, C. (1991). Macrophage deactivation by interleukin 10. The Journal of Experimental Medicine, 174(6), 1549-1555.
42. Williams, L. M., Ricchetti, G., Sarma, U., Smallie, T., & Foxwell, B. M. (2004). Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology, 113(3), 281-292.
43. Crepaldi, L., Gasperini, S., Lapinet, J. A., Calzetti, F., Pinardi, C., Liu, Y., et al. (2001). Up-regulation of IL-10R1 expression is required to render human neutrophils fully responsive to IL-10. Journal of Immunology, 167(4), 2312-2322.
44. Kotenko, S. V., & Pestka, S. (2000). Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene, 19(21), 2557-2565.
45. Jurlander, J., Lai, C. F., Tan, J., Chou, C. C., Geisler, C. H., Schriber, J., et al. (1997). Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood, 89(11), 4146-4152.
46. Denning, T. L., Campbell, N. A., Song, F., Garofalo, R. P., Klimpel, G. R., Reyes, V. E., et al. (2000). Expression of IL-10 receptors on epithelial cells from the murine small and large intestine. International Immunology, 12(2), 133-139.
47. Wolk, K., Kunz, S., Asadullah, K., & Sabat, R. (2002). Cutting edge: immune cells as sources and targets of the IL-10 family members? Journal of Immunology, 168(11), 5397-5402.
48. Wolk, K., Witte, E., Reineke, U., Witte, K., Friedrich, M., Sterry, W., et al. (2005). Is there an interaction between interleukin-10 and interleukin-22? Genes and Immunity, 6(1), 8-18.
49. Sheikh, F., Baurin, V. V., Lewis-Antes, A., Shah, N. K., Smirnov, S. V., Anantha, S., et al. (2004). Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. Journal of Immunology, 172(4), 2006-2010.
50. Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., et al. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology, 4(1), 63-68.
51. Srividya, S., Roy, R. P., Basu, S. K., & Mukhopadhyay, A. (2000). Scavenger receptor-mediated delivery of muramyl dipeptide activates antitumor efficacy of macrophages by enhanced secretion of tumor-suppressive cytokines. Journal of Leukocyte Biology, 67(5), 683-690.
52. Tsuji-Takayama, K., Suzuki, M., Yamamoto, M., Harashima, A., Okochi, A., Otani, T., et al. (2008). IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT. Experimental hematology, 36(2), 181-192.
53. Sabat, R., Grutz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., et al. (2010). Biology of interleukin-10. Cytokine & Growth Factor Reviews, 21(5), 331-344.
54. Carson, W. E., Lindemann, M. J., Baiocchi, R., Linett, M., Tan, J. C., Chou, C. C., et al. (1995). The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood, 85(12), 3577-3585.
55. Sabat, R. (2010). IL-10 family of cytokines. Cytokine & Growth Factor Reviews, 21(5), 315-324.
56. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O'Garra, A. (1991). IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology, 147(11), 3815-3822.
57. de Waal Malefyt, R., Figdor, C. G., Huijbens, R., Mohan-Peterson, S., Bennett, B., Culpepper, J., et al. (1993). Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. Journal of Immunology, 151(11), 6370-6381.
58. Gruber, M. F., Williams, C. C., & Gerrard, T. L. (1994). Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 beta and inhibited by IL-4 and IL-10. Journal of Immunology, 152(3), 1354-1361.
59. Wolk, K., Witte, K., Witte, E., Proesch, S., Schulze-Tanzil, G., Nasilowska, K., et al. (2008). Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. Journal of Leukocyte Biology, 83(5), 1181-1193.
60. Mitra, R. S., Judge, T. A., Nestle, F. O., Turka, L. A., & Nickoloff, B. J. (1995). Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. Journal of Immunology, 154(6), 2668-2677.
61. Hagmann, W. K., Durette, P. L., Lanza, T., Kevin, N. J., de Laszlo, S. E., Kopka, I. E., et al. (2001). The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. Bioorganic & Medicinal Chemistry Letters, 11(20), 2709-2713.
62. Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology, 19, 683-765.
63. Cassatella, M. A., Meda, L., Gasperini, S., Calzetti, F., & Bonora, S. (1994). Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. The Journal of Experimental Medicine, 179(5), 1695-1699.
64. Cassatella, M. A., Gasperini, S., Calzetti, F., Bertagnin, A., Luster, A. D., & McDonald, P. P. (1997). Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. European Journal of Immunology, 27(1), 111-115.
65. Gasperini, S., Marchi, M., Calzetti, F., Laudanna, C., Vicentini, L., Olsen, H., et al. (1999). Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. Journal of Immunology, 162(8), 4928-4937.
66. Marie, C., Pitton, C., Fitting, C., & Cavaillon, J. M. (1996). IL-10 and IL-4 synergize with TNF-alpha to induce IL-1ra production by human neutrophils. Cytokine, 8(2), 147-151.
67. Taga, K., Mostowski, H., & Tosato, G. (1993). Human interleukin-10 can directly inhibit T-cell growth. Blood, 81(11), 2964-2971.
68. Schandene, L., Alonso-Vega, C., Willems, F., Gerard, C., Delvaux, A., Velu, T., et al. (1994). B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. Journal of Immunology, 152(9), 4368-4374.
69. Briere, F., Bridon, J. M., Chevet, D., Souillet, G., Bienvenu, F., Guret, C., et al. (1994). Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. The Journal of Clinical Investigation, 94(1), 97-104.
70. Llorente, L., Zou, W., Levy, Y., Richaud-Patin, Y., Wijdenes, J., Alcocer-Varela, J., et al. (1995). Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. The Journal of Experimental Medicine, 181(3), 839-844.
71. al-Janadi, M., al-Dalaan, A., al-Balla, S., al-Humaidi, M., & Raziuddin, S. (1996). Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. Journal of Clinical Immunology, 16(4), 198-207.
72. Llorente, L., Richaud-Patin, Y., Fior, R., Alcocer-Varela, J., Wijdenes, J., Fourrier, B. M., et al. (1994). In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis and Rheumatism, 37(11), 1647-1655.
73. Kunz, S., Wolk, K., Witte, E., Witte, K., Doecke, W. D., Volk, H. D., et al. (2006). Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Experimental Dermatology, 15(12), 991-1004.
74. Holland, D. B., Bojar, R. A., Farrar, M. D., & Holland, K. T. (2009). Differential innate immune responses of a living skin equivalent model colonized by Staphylococcus epidermidis or Staphylococcus aureus. FEMS Microbiology Letters, 290(2), 149-155.
75. Tohyama, M., Hanakawa, Y., Shirakata, Y., Dai, X., Yang, L., Hirakawa, S., et al. (2009). IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. European Journal of Immunology, 39(10), 2779-2788.
76. Wolk, K., Witte, E., Warszawska, K., Schulze-Tanzil, G., Witte, K., Philipp, S., et al. (2009). The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis. European Journal of Immunology, 39(12), 3570-3581.
77. Becherel, P. A., Le Goff, L., Ktorza, S., Ouaaz, F., Mencia-Huerta, J. M., Dugas, B., et al. (1995). Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes. European Journal of Immunology, 25(10), 2992-2995.
78. Pan, H. F., Li, X. P., Zheng, S. G., & Ye, D. Q. (2013). Emerging role of interleukin-22 in autoimmune diseases. Cytokine & Growth Factor Reviews, 24(1), 51-57.
79. Massey, E. J., Sundstedt, A., Day, M. J., Corfield, G., Anderton, S., & Wraith, D. C. (2002). Intranasal peptide-induced peripheral tolerance: the role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis. Veterinary Immunology and Immunopathology, 87(3-4), 357-372.
80. Akahoshi, M., Nakashima, H., Tanaka, Y., Kohsaka, T., Nagano, S., Ohgami, E., et al. (1999). Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis and Rheumatism, 42(8), 1644-1648.
81. Teichmann, L. L., Kashgarian, M., Weaver, C. T., Roers, A., Muller, W., & Shlomchik, M. J. (2012). B cell-derived IL-10 does not regulate spontaneous systemic autoimmunity in MRL. Fas(lpr) mice. Journal of Immunology, 188(2), 678-685.
82. Mannoor, K., Matejuk, A., Xu, Y., Beardall, M., & Chen, C. (2012). Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. Journal of Immunology, 188(8), 3628-3638.
83. Lee, T. P., Tang, S. J., Wu, M. F., Song, Y. C., Yu, C. L., & Sun, K. H. (2010). Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. Journal of Autoimmunity, 35(4), 358-367.
84. Llorente, L., Richaud-Patin, Y., Garcia-Padilla, C., Claret, E., Jakez-Ocampo, J., Cardiel, M. H., et al. (2000). Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis and Rheumatism, 43(8), 1790-1800.
85. Miret, C., Font, J., Molina, R., Garcia-Carrasco, M., Filella, X., Ramos, M., et al. (2001). Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Research, 21(4B), 3053-3059.
86. Rianthavorn, P., Chokedeemeeboon, C., Deekajorndech, T., & Suphapeetiporn, K. (2013). Interleukin-10 promoter polymorphisms and expression in Thai children with juvenile systemic lupus erythematosus. Lupus, 22(7), 721-726.
87. Arora, V., Verma, J., Marwah, V., Kumar, A., Anand, D., & Das, N. (2012). Cytokine imbalance in systemic lupus erythematosus: A study on northern Indian subjects. Lupus, 21(6), 596-603.
88. Chong, W. P., Ip, W. K., Wong, W. H., Lau, C. S., Chan, T. M., & Lau, Y. L. (2004). Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus. Genes and Immunity, 5(6), 484-492.
89. Peng, H., Liu, C. Y., Zhou, M., Wen, P. F., Zhang, M., Qiu, L. J., et al. (2013). IL-10RB rs2834167 (A/G) polymorphism is associated with the susceptibility to systemic lupus erythematosus: Evidence from a study in Chinese han population. Inflammation, 36(6), 1218-1224.
90. Song, G. G., Choi, S. J., Ji, J. D., & Lee, Y. H. (2013). Associations between interleukin-10 polymorphisms and susceptibility to systemic lupus erythematosus: A meta-analysis. Human Immunology, 74(3), 364-370.
91. Hashizume, M., & Mihara, M. (2011). The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis, 2011, 765624.
92. van Roon, J., Wijngaarden, S., Lafeber, F. P., Damen, C., van de Winkel, J., & Bijlsma, J. W. (2003). Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. The Journal of Rheumatology, 30(4), 648-651.
93. Zhang, J., Zhang, Y., Jin, J., Li, M., Xie, K., Wen, C., et al. (2011). The -1082A/G polymorphism in the Interleukin-10 gene and the risk of rheumatoid arthritis: A meta-analysis. Cytokine, 56(2), 351-355.
94. Saito, I., Haruta, K., Shimuta, M., Inoue, H., Sakurai, H., Yamada, K., et al. (1999). Fas ligand-mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL-10. Journal of Immunology, 162(5), 2488-2494.
95. Strack, P., Martin, C., Saito, S., Dekruyff, R. H., & Ju, S. T. (1990). Metabolic inhibitors distinguish cytolytic activity of CD4 and CD8 clones. European Journal of Immunology, 20(1), 179-184.
96. Turner, D. M., Williams, D. M., Sankaran, D., Lazarus, M., Sinnott, P. J., & Hutchinson, I. V. (1997). An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics, 24(1), 1-8.
97. Tarzi, M., Klunker, S., Texier, C., Verhoef, A., Stapel, S. O., Akdis, C. A., et al. (2006). Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clinical and Experimental Allergy, 36(4), 465-474.
98. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., & Sica, A. (2002). Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23(11), 549-555.
99. Bikker, A., van Woerkom, J. M., Kruize, A. A., Wenting-van Wijk, M., de Jager, W., Bijlsma, J. W., et al. (2010). Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjogren's syndrome correlates with increased inflammation. Arthritis and Rheumatism, 62(4), 969-977.
100. Hulkkonen, J., Pertovaara, M., Antonen, J., Lahdenpohja, N., Pasternack, A., & Hurme, M. (2001). Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren's syndrome. Arthritis and Rheumatism, 44(1), 176-179.
101. Lee, M. S., Wogensen, L., Shizuru, J., Oldstone, M. B., & Sarvetnick, N. (1994). Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. The Journal of Clinical Investigation, 93(3), 1332-1338.
102. Lee, M. S., Mueller, R., Wicker, L. S., Peterson, L. B., & Sarvetnick, N. (1996). IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. The Journal of Experimental Medicine, 183(6), 2663-2668.
103. Munz, C., Lunemann, J. D., Getts, M. T., & Miller, S. D. (2009). Antiviral immune responses: Triggers of or triggered by autoimmunity? Nature Reviews Immunology, 9(4), 246-258.
104. Kakalacheva, K., Munz, C., & Lunemann, J. D. (2011). Viral triggers of multiple sclerosis. Biochimica et Biophysica Acta, 1812(2), 132-140.
105. Mi, W., Prentice, T. W., Young, C. R., Johnson, R. R., Sieve, A. N., Meagher, M. W., et al. (2006). Restraint stress decreases virus-induced pro-inflammatory cytokine mRNA expression during acute Theiler's virus infection. Journal of Neuroimmunology, 178(1-2), 49-61.
106. Rodriguez, M., Zoecklein, L. J., Howe, C. L., Pavelko, K. D., Gamez, J. D., Nakane, S., et al. (2003). Gamma interferon is critical for neuronal viral clearance and protection in a susceptible mouse strain following early intracranial Theiler's murine encephalomyelitis virus infection. Journal of Virology, 77(22), 12252-12265.
107. Herder, V., Gerhauser, I., Klein, S. K., Almeida, P., Kummerfeld, M., Ulrich, R., et al. (2012). Interleukin-10 expression during the acute phase is a putative prerequisite for delayed viral elimination in a murine model for multiple sclerosis. Journal of Neuroimmunology, 249(1-2), 27-39.
108. Maris, C. H., Chappell, C. P., & Jacob, J. (2007). Interleukin-10 plays an early role in generating virus-specific T cell anergy. BMC Immunology, 8, 8.
109. Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., et al. (2006). Resolution of a chronic viral infection after interleukin-10 receptor blockade. The Journal of Experimental Medicine, 203(11), 2461-2472.
110. Bai, F., Town, T., Qian, F., Wang, P., Kamanaka, M., Connolly, T. M., et al. (2009). IL-10 signaling blockade controls murine West Nile virus infection. PLoS Pathogens, 5(10), e1000610.
111. Xin, J., Wainwright, D. A., Mesnard, N. A., Serpe, C. J., Sanders, V. M., & Jones, K. J. (2011). IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection. Brain, Behavior, and Immunity, 25(5), 820-829.
112. Molina-Holgado, E., Vela, J. M., Arevalo-Martin, A., & Guaza, C. (2001). LPS/IFN-gamma cytotoxicity in oligodendroglial cells: Role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. The European Journal of Neuroscience, 13(3), 493-502.
113. Larmonier, C. B., Uno, J. K., Lee, K. M., Karrasch, T., Laubitz, D., Thurston, R., et al. (2008). Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. American Journal of Physiology-Gastrointestinal and Liver Physiology, 295(5), G1079-G1091.
114. Wang, A. H., Lam, W. J., Han, D. Y., Ding, Y., Hu, R., Fraser, A. G., et al. (2011). The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Human Immunology, 72(5), 431-435.
115. Zhu, H., Lei, X., Liu, Q., & Wang, Y. (2013). Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: A meta-analysis based on 17, 585 subjects. Cytokine, 61(1), 146-153.
116. Bloch, D. B., Nobre, R., Steinbicker, A. U., Al-Herz, W., Notarangelo, L. D., & Recher, M. (2012). Decreased IL-10 production by EBV-transformed B cells from patients with VODI: Implications for the pathogenesis of Crohn disease. The Journal of Allergy and Clinical Immunology, 129(6), 1678-1680.
117. Schoenbein, C., Docke, W. D., Wolk, K., Belbe, G., Hoflich, C., Jung, M., et al. (2008). Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type. Clinical and Experimental Immunology, 151(2), 306-316.
118. Lingnau, M., Hoflich, C., Volk, H. D., Sabat, R., & Docke, W. D. (2007). Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Human Immunology, 68(9), 730-738.
119. Allavena, P., Piemonti, L., Longoni, D., Bernasconi, S., Stoppacciaro, A., Ruco, L., et al. (1998). IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. European Journal of Immunology, 28(1), 359-369.
120. Seifert, M., Sterry, W., Effenberger, E., Rexin, A., Friedrich, M., Haeussler-Quade, A., et al. (2000). The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Archives of Dermatological Research, 292(4), 164-172.
121. Eskdale, J., Wordsworth, P., Bowman, S., Field, M., & Gallagher, G. (1997). Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens, 49(6), 635-639.
122. Borska, L., Andrys, C., Krejsek, J., Hamakova, K., Kremlacek, J., Ettler, K., et al. (2008). Serum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen. International Journal of Dermatology, 47(8), 800-805.
123. Pacheco, K. A., Tarkowski, M., Sterritt, C., Negri, J., Rosenwasser, L. J., & Borish, L. (2001). The influence of diesel exhaust particles on mononuclear phagocytic cell-derived cytokines: IL-10, TGF-beta and IL-1 beta. Clinical and Experimental Immunology, 126(3), 374-383.
124. Buruiana, F. E., Sola, I., & Alonso-Coello, P. (2010). Recombinant human interleukin 10 for induction of remission in Crohn's disease. The Cochrane Database of Systematic Reviews, 11, CD005109.
125. Schreiber, S., Fedorak, R. N., Nielsen, O. H., Wild, G., Williams, C. N., Nikolaus, S., et al. (2000). Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group. Gastroenterology, 119(6), 1461-1472.
126. Bettelli, E., Das, M. P., Howard, E. D., Weiner, H. L., Sobel, R. A., & Kuchroo, V. K. (1998). IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. Journal of Immunology, 161(7), 3299-3306.
127. Kennedy, M. K., Torrance, D. S., Picha, K. S., & Mohler, K. M. (1992). Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. Journal of Immunology, 149(7), 2496-2505.
128. O'Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., & Hawrylowicz, C. (2008). Strategies for use of IL-10 or its antagonists in human disease. Immunological Reviews, 223, 114-131.
129. Barrat, F. J., Cua, D. J., Boonstra, A., Richards, D. F., Crain, C., Savelkoul, H. F., et al. (2002). In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. The Journal of Experimental Medicine, 195(5), 603-616.
130. Johansson, A. C., Hansson, A. S., Nandakumar, K. S., Backlund, J., & Holmdahl, R. (2001). IL-10-deficient B10. Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. Journal of Immunology, 167(6), 3505-3512.
131. Clausen, B. E., & Girard-Madoux, M. J. (2013). IL-10 control of dendritic cells in the skin. Oncoimmunology, 2(3), e23186.
132. Paul, G., Khare, V., & Gasche, C. (2012). Inflamed gut mucosa: downstream of interleukin-10. European Journal of Clinical Investigation, 42(1), 95-109.
133. Mosser, D. M., & Zhang, X. (2008). Interleukin-10: New perspectives on an old cytokine. Immunological Reviews, 226, 205-218.
134. Lenert, P., Goeken, A., Handwerger, B. S., & Ashman, R. F. (2003). Innate immune responses in lupus-prone Palmerston North mice: Differential responses to LPS and bacterial DNA/CpG oligonucleotides. Journal of Clinical Immunology, 23(3), 202-213.
135. Zandman-Goddard, G., & Shoenfeld, Y. (2003). Novel approaches to therapy for SLE. Clinical Reviews in Allergy and Immunology, 25(1), 105-112.
136. Porrini, A. M., De Luca, G., Gambi, D., & Reder, A. T. (1998). Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. Journal of Neuroimmunology, 81(1-2), 109-115.